BR112013033671A2 - composições de polipeptídeo de fusão fc livre de arginina e métodos de uso - Google Patents
composições de polipeptídeo de fusão fc livre de arginina e métodos de usoInfo
- Publication number
- BR112013033671A2 BR112013033671A2 BR112013033671A BR112013033671A BR112013033671A2 BR 112013033671 A2 BR112013033671 A2 BR 112013033671A2 BR 112013033671 A BR112013033671 A BR 112013033671A BR 112013033671 A BR112013033671 A BR 112013033671A BR 112013033671 A2 BR112013033671 A2 BR 112013033671A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- arginine free
- fusion polypeptide
- polypeptide compositions
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000004475 Arginine Substances 0.000 title abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000006472 autoimmune response Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
resumo patente de invenção: "composições de polipeptídeo de fusão fc livre de arginina e métodos de uso". a presente invenção refere-se a composições contendo polipep-tídeo livre de arginina e a métodos para tratar distúrbios associados com inflamação ou a resposta autoimune. em particular, o polipeptídeo é etaner-cepte.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504110P | 2011-07-01 | 2011-07-01 | |
US61/504,110 | 2011-07-01 | ||
PCT/US2012/044988 WO2013006454A1 (en) | 2011-07-01 | 2012-06-29 | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013033671A2 true BR112013033671A2 (pt) | 2017-01-24 |
BR112013033671B1 BR112013033671B1 (pt) | 2022-10-18 |
Family
ID=46579322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013033671-4A BR112013033671B1 (pt) | 2011-07-01 | 2012-06-29 | Composições de polipeptídeo de fusão fc livre de arginina e uso |
Country Status (13)
Country | Link |
---|---|
US (2) | US10995130B2 (pt) |
EP (1) | EP2726090B1 (pt) |
JP (2) | JP6463968B2 (pt) |
KR (1) | KR102061355B1 (pt) |
CN (2) | CN103930124B (pt) |
AU (2) | AU2012279205B2 (pt) |
BR (1) | BR112013033671B1 (pt) |
CA (1) | CA2840711C (pt) |
DK (1) | DK2726090T3 (pt) |
EA (1) | EA026226B1 (pt) |
MX (2) | MX358137B (pt) |
WO (1) | WO2013006454A1 (pt) |
ZA (1) | ZA201400490B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
KR20210032558A (ko) * | 2011-06-28 | 2021-03-24 | 인히브릭스, 인크. | 세르핀 융합 폴리펩타이드 및 이의 이용 방법 |
CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
PT2768525T (pt) * | 2011-10-18 | 2019-07-17 | Coherus Biosciences Inc | Formulações etanercept estabilizadas com iões de magnésio |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
IN2015KN00005A (pt) * | 2012-07-09 | 2015-07-31 | Coherus Biosciences Inc | |
LT2892550T (lt) | 2012-09-07 | 2020-04-10 | Coherus Biosciences, Inc. | Stabilios adalimumabo vandeninės kompozicijos |
ES2657377T3 (es) * | 2012-09-11 | 2018-03-05 | Coherus Biosciences, Inc. | Etanercept plegado correctamente con alta pureza y excelente rendimiento |
KR101419884B1 (ko) | 2012-11-27 | 2014-07-16 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
US20160106844A1 (en) * | 2013-05-02 | 2016-04-21 | Mabxience, S.A. | Alternative formulations for tnfr: fc fusion polypeptides |
WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Meiji Seikaファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
HUE029849T2 (en) | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
CA2970577A1 (en) * | 2014-12-22 | 2016-06-30 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2016149139A1 (en) * | 2015-03-13 | 2016-09-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
EP3533441A4 (en) * | 2016-10-28 | 2019-12-04 | Celltrion Inc. | STABLE PHARMACEUTICAL FORMULATION |
US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
GB201901547D0 (en) | 2019-02-05 | 2019-03-27 | Arecor Ltd | Stabilized Fc Fusion protein solutions |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
AU4363200A (en) | 1999-04-19 | 2000-11-02 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
KR20040085185A (ko) | 2002-02-14 | 2004-10-07 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
DE60322513D1 (de) | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilisierte TNFR-Fc Formulierung mit Arginin |
EP1946776B1 (en) * | 2002-02-27 | 2017-01-18 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
KR100471843B1 (ko) | 2002-06-11 | 2005-03-08 | 현대자동차주식회사 | 자동차의 아웃사이드 웨더스트립 장착구조 |
DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
US8937045B2 (en) * | 2003-02-28 | 2015-01-20 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding proteins |
AU2004262014B2 (en) | 2003-08-01 | 2010-06-17 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
AU2006259664A1 (en) * | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
WO2007124082A2 (en) * | 2006-04-21 | 2007-11-01 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
PE20080857A1 (es) | 2006-10-20 | 2008-08-19 | Amgen Inc | Formulaciones a base de polipeptidos estables |
JP2010523695A (ja) * | 2007-04-11 | 2010-07-15 | アルコン リサーチ, リミテッド | アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのTNFαのインヒビターおよび抗ヒスタミン薬の使用 |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
WO2012013980A1 (en) * | 2010-07-30 | 2012-02-02 | Arecor Limited | Stabilized aqueous antibody compositions |
CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
-
2012
- 2012-06-29 CN CN201280032584.XA patent/CN103930124B/zh active Active
- 2012-06-29 CA CA2840711A patent/CA2840711C/en active Active
- 2012-06-29 MX MX2014000093A patent/MX358137B/es active IP Right Grant
- 2012-06-29 EA EA201490195A patent/EA026226B1/ru unknown
- 2012-06-29 WO PCT/US2012/044988 patent/WO2013006454A1/en active Application Filing
- 2012-06-29 US US14/128,846 patent/US10995130B2/en active Active
- 2012-06-29 KR KR1020147001595A patent/KR102061355B1/ko active IP Right Grant
- 2012-06-29 CN CN202110408576.1A patent/CN113244374A/zh active Pending
- 2012-06-29 AU AU2012279205A patent/AU2012279205B2/en active Active
- 2012-06-29 DK DK12738670.4T patent/DK2726090T3/da active
- 2012-06-29 BR BR112013033671-4A patent/BR112013033671B1/pt active IP Right Grant
- 2012-06-29 EP EP12738670.4A patent/EP2726090B1/en active Active
- 2012-06-29 JP JP2014519158A patent/JP6463968B2/ja active Active
-
2014
- 2014-01-07 MX MX2018009524A patent/MX2018009524A/es unknown
- 2014-01-21 ZA ZA2014/00490A patent/ZA201400490B/en unknown
-
2017
- 2017-05-18 JP JP2017098806A patent/JP2017186349A/ja active Pending
- 2017-11-21 AU AU2017265026A patent/AU2017265026B2/en active Active
-
2021
- 2021-03-30 US US17/216,769 patent/US11834491B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017265026B2 (en) | 2019-10-24 |
EP2726090A1 (en) | 2014-05-07 |
AU2017265026A1 (en) | 2017-12-07 |
CN103930124A (zh) | 2014-07-16 |
EA026226B1 (ru) | 2017-03-31 |
KR102061355B1 (ko) | 2019-12-31 |
EP2726090B1 (en) | 2020-01-01 |
CA2840711C (en) | 2023-10-17 |
AU2012279205A1 (en) | 2014-02-06 |
WO2013006454A1 (en) | 2013-01-10 |
DK2726090T3 (da) | 2020-01-20 |
JP2017186349A (ja) | 2017-10-12 |
JP2014518276A (ja) | 2014-07-28 |
ZA201400490B (en) | 2017-09-27 |
US10995130B2 (en) | 2021-05-04 |
CN113244374A (zh) | 2021-08-13 |
CN103930124B (zh) | 2021-05-11 |
KR20140056218A (ko) | 2014-05-09 |
MX358137B (es) | 2018-08-06 |
CA2840711A1 (en) | 2013-01-10 |
BR112013033671B1 (pt) | 2022-10-18 |
AU2012279205B2 (en) | 2017-08-31 |
MX2014000093A (es) | 2014-11-12 |
NZ620160A (en) | 2016-07-29 |
US11834491B2 (en) | 2023-12-05 |
MX2018009524A (es) | 2021-11-16 |
US20210309719A1 (en) | 2021-10-07 |
EA201490195A1 (ru) | 2014-04-30 |
US20140255400A1 (en) | 2014-09-11 |
JP6463968B2 (ja) | 2019-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013033671A2 (pt) | composições de polipeptídeo de fusão fc livre de arginina e métodos de uso | |
WO2014144960A3 (en) | Fc variants | |
BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
BR112013026883A2 (pt) | Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica | |
BR112012030179A8 (pt) | Polipeptídeo contendo fc | |
BR112014008529A2 (pt) | il-6 humanizado e receptor de il-6 | |
TR201902516T4 (tr) | Glukagon-glp-1-gıp üçlü agonist bileşikleri. | |
BR112014033116A2 (pt) | anticorpos para tau | |
BR112015016395A2 (pt) | pirazóis 3-substituídos e uso como inibidores de dlk | |
BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
HK1190341A1 (zh) | 脫敏血清結合領域和其擴展血清半衰期的用途 | |
BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
NZ709059A (en) | Immunotherapy with binding agents | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
BR112014030060A2 (pt) | compostos de tetra-hidropirazolopirimidina | |
BR112013028908A2 (pt) | anticorpos c-kit e usos dos mesmos | |
EA201391773A1 (ru) | Клетки-предшественники мезодермальной линии | |
BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
BR112015001344A2 (pt) | xilose isomerases e seus usos | |
MX2019009104A (es) | Matrices de soporte derivadas de tn3 especificas para cd40l y sus metodos de empleo. | |
GT201300313A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN MA INC. (US) |
|
B25I | Requirement for requested change of headquarter |
Owner name: BIOGEN MA INC. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: BIOGEN MA INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |